Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

Background: Apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen (PSA) progression in the placebo-controlled SPARTAN study of high-risk nonmetastatic castration-resistant prostate cance...

Full description

Bibliographic Details
Main Authors: Bhaumik, A. (Author), Chowdhury, S. (Author), Feng, F.Y (Author), Graff, J.N (Author), Hadaschik, B.A (Author), Londhe, A. (Author), Lopez-Gitlitz, A. (Author), Mundle, S.D (Author), Olmos, D. (Author), Oudard, S. (Author), Saad, F. (Author), Small, E.J (Author), Smith, M.R (Author), Thomas, S. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
adult
adverse event
Androgen antagonists
androgen deprivation therapy
apalutamide
Article
cancer patient
cancer prognosis
cancer survival
castration resistant prostate cancer
clinical outcome
controlled study
human
kinetics
major clinical study
male
metastasis free survival
Nonmetastatic castration-resistant prostate cancer
overall survival
phase 3 clinical trial
placebo
prostate cancer
prostate specific antigen
Prostate-specific antigen kinetics
Prostatic neoplasm
randomized controlled trial
treatment outcome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items